Araştırma Makalesi


DOI :10.26650/jchild.2021.1.844098   IUP :10.26650/jchild.2021.1.844098    Tam Metin (PDF)

Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi

Yöntem YamanMurat ElliKürşat ÖzdilliLeyla TelhanNihan BayramVolkan HazarEbru Tuğrul SarıbeyoğluŞifa ŞahinSeniye Sema Anak

Giriş: Standart tedavi alan Hodgkin Lymphoma (HL) hastalarının yaklaşık %20’sinde hastalık dirençli seyredebilir veya tekrar edebilir. Tekrar eden/dirençli HL’da standart tedavi yüksek doz kemoterapi ve takip eden otolog kök hücre naklidir (OKHN). Otolog KHN sonrası tekrar eden hastalarda ise allojeneik kök hücre nakli (AKHN) önemli bir kurtarma tedavisi olarak görülmektedir. 

Amaç: Medipol Üniversitesi Tıp Fakültesi çocuk kemik iliği nakil ünitesinde OKHN ve AKHN yapılan hastalarda sonuçları değerlendirmek. 

Yöntem: Tekrar eden/dirençli HL nedeniyle 2014 Kasım ile Temmuz 2019 tarihleri arasında merkezimizde OKHN yapılan 18 olgu retrospektif olarak değerlendirilmiştir. Otolog KHN sonrası hastalığı tekrar eden ve AKHN yapılan hastalarda ayrıca değerlendirilmiştir. 

Bulgular: Onaltı hasta halen hayattadır. Onbir hastada OKHN sonrası hastalık tekrar etmiştir. Relaps eden hastalardan 10’una AKHN yapılmıştır. Bu hastalardan üçünde tekrar görülmüş olup, sekizi nakil sonrası hayattadırlar.

DOI :10.26650/jchild.2021.1.844098   IUP :10.26650/jchild.2021.1.844098    Tam Metin (PDF)

Hematopoietic Stem Cell Transplantation and High Dose Chemotherapy in Recurrent and/or Chemotherapy Resistant Hodgkin Lymphoma Cases: A Single Center Experience

Yöntem YamanMurat ElliKürşat ÖzdilliLeyla TelhanNihan BayramVolkan HazarEbru Tuğrul SarıbeyoğluŞifa ŞahinSeniye Sema Anak

Background: Nearly 20% of patients with Hodgkin Lymphoma (HL) who receive standard treatment will relapse or have a refractory disease. Standard treatment for the Relapsed/Refractory (RR) HL is salvage high dose chemotherapy followed by autologous stem cell transplantation (AuSCT). Management of RR HL after AuSCT with allogeneic stem cell transplantation (ASCT) is also considered as an important salvage therapy.

Objective: To describe the outcome in pediatric patients with RR HL who underwent AuHSCT and ASCT in Medipol University hematopoietic stem cell transplantation center. 

Method: We retrospectively evaluated 18 pediatric patients with RR HL who underwent AHSCT between November 2014 and July 2019. The evaluation of ASCT after RR HL AuSCT is also done. 

Results: Sixteen patients are still alive. Eleven of them relapsed after AuHSCT. AllogeneicHSCT was performed on 10 patients who relapsed. Relapse was seen in three patients after AHSCT. Eight of them are still alive.


PDF Görünüm

Referanslar

  • 1. Körholz CM, Metzger ML, Kelly KM, Schwartz CL, Castellanos EM, Dieckmann, et al. Pediatric Hodgkin Lymphoma. J Clin Oncol 2015;33(27):2975-85. google scholar
  • 2. Schellong G, Bramswig J, Ludwig R, Gerein V, Jobke A, Jürgens H, et al. Combined treatment strategy in over 200 children with Hodgkin’s disease: Graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy—A report of the cooperative therapy study DAL-HD-82 [in German]. Klin Pädiatr 1986;98:137-46. google scholar
  • 3. Weiner MA, Leventhal BG, Marcus R, Brecher M, Ternberg J, Behm FG, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: A Pediatric Oncology Group study. J Clin Oncol 1991;9:1591-8. google scholar
  • 4. Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O’Brien RT, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: Results of the Children’s Cancer Group phase III trial. J Clin Oncol 1998;16:897-906. google scholar
  • 5. Schellong G, Potter R, Bramswig J, Wagner W, Prott FG, Dörffel W, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin’s disease: The German-Austrian multicenter trial DAL-HD-90 The German-Austrian Pediatric Hodgkin’s Disease study group. J Clin Oncol 1999;17:3736-44. google scholar
  • 6. Donaldson SS, Link MP, Weinstein HJ, Rai SN, Brain S, Billett AL, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin’s disease. J Clin Oncol 2007;25:332-7. google scholar
  • 7. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, et al. ABVD versus BEACOPP for Hodgkin’s Lymphoma When High-Dose Salvage Is Planned. N Engl J Med 2011;365(3):203–12. google scholar
  • 8. Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med 2016;374:2419–29. google scholar
  • 9. Lohri A, Barnett M, Fairey RN, O’Reilly SE, Phillips GL, Reece D, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991;77(10):2292–98. google scholar
  • 10. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma. Biol Blood Marrow Transplant 2006;12(10):1065–72. google scholar
  • 11. Satish Shanbhag and Richard Ambinder. Hodgkin Lymphoma: a review and update on recent progress. CA Cancer J Clin 2018;68(2):116–32. google scholar
  • 12. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Pettengell, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone marrow transplant 2008;41(9):765–70. google scholar
  • 13. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–87. google scholar
  • 14. Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation. Bone marrow transplant 2008; 41(9):765–70. google scholar
  • 15. Porter DL, Stadtmauer EA, Lazarus HM. ‘GVHD’: graft-versus-host disease or graft-versus-Hodgkin’s disease? An old acronym with new meaning. Bone marrow transplant 2003;31(9):739–46. google scholar
  • 16. Sureda A, Robinson S, Canals C, Carella AM, Booagerts MA, Caballeros D, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin’s Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26(3):455–62. google scholar
  • 17. Burroughs LM, O’Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14(11):1279–87. google scholar
  • 18. Moskowitz CH, Nimer SD, Zelenetz VAD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97:616–23. google scholar
  • 19. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Circhner HH, et al. Time intensified dexamethasone-cisplatin-cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:1628–35. google scholar
  • 20. Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and nontoxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762–67. google scholar
  • 21. Proctor SJ, Jackson GH, Lennard A, Angus B, Wood K, Lucraft HL, et al. Strategic approach to the management of Hodgkin’s disease incorporating salvage therapy with highdose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol 2003;14:47–50. google scholar
  • 22. Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegilated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007;18:1071-9. google scholar
  • 23. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematological 2007;92:35–41. google scholar
  • 24. Labrador J, Cabrero-Calvo M, Perez-Lopez E, Mattheos MV, Vasquez L, Caballero MD, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol 2014;93:1745–53. google scholar
  • 25. Moskowitz AJ, Herrera AF, Beawen AW. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy. ASCO educational book 2019;39:476-85. google scholar
  • 26. Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2015;21:2136–40. google scholar
  • 27. Alessandro Broccoli and Pier Luigi Zinzani. The role of transplantation in Hodgkin lymphoma. Br J Haematol 2019;84:93–104. google scholar
  • 28. Cassaday RD, Fromm J, Cowan AJ, Libby EN, Philip M, Behnia S, et al. Safety and activity of brentuximab vedotin (BV) plus ifosfanide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): initial results of a phase I/II study. Blood 2016;128:1834. google scholar
  • 29. Garcia-Sanz R, Sureda A, Gonzalez AP, Canales M, Gonzalez AP, Pinana JL, et al. Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Blood 2016;128:1109. google scholar
  • 30. Hagenbeek A, Zijlstra JM, Lugtenburg P, Lugtenburg P, Van İmhof G, Nijland M, et al. Transplant BRaVE: combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: a hase 1 dose-escalation study. Haematologica 2016;101:44. google scholar
  • 31. O’Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalacet M, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, singlearm, phase 1-2 trial. Lancet Oncol 2018;19:257–66. google scholar
  • 32. LaCasce AS, Bociek G, Sawas A, Caimi P, Agura E, Matous J, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018;132:40–8. google scholar
  • 33. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer 1996;78:1293–9. google scholar
  • 34. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol 2015;16:625–33. google scholar
  • 35. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2015;385:1853–62. google scholar
  • 36. Gajevski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 1996;14: 572–8. google scholar
  • 37. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the lymphoma working party of the European group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455–62. google scholar
  • 38. Robinson, SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009;94:230–8. google scholar
  • 39. Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espa~nol de Linfomas/Trasplante de Medula Osea (GELTAMO) and the Lymphoma Working Party of the European group for Blood and Marrow Transplantation. Haematologica 2012;97:310–7. google scholar
  • 40. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F , Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant 2014;49:190-4. google scholar
  • 41. Castagna L, Bramanti S, Devillier R, Sarina B, Crocchiolo R, Furst S, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplant 2017;52:683-8. google scholar
  • 42. Abdalla A, Hammad M, Hafez H, Zaghloul MS, Taha H, El‐Hennawy G, et al. Outcome predictors of autologous hematopoietic stem cell transplantation in children with relapsed and refractory Hodgkin lymphoma: Single‐center experience in a lower‐ middle‐income country. Pediatr Transplant 2019;23:e13531 google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Yaman, Y., Elli, M., Özdilli, K., Telhan, L., Bayram, N., Hazar, V., Tuğrul Sarıbeyoğlu, E., Şahin, Ş., & Anak, S.S. (2021). Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi. Çocuk Dergisi, 21(1), 7-12. https://doi.org/10.26650/jchild.2021.1.844098


AMA

Yaman Y, Elli M, Özdilli K, Telhan L, Bayram N, Hazar V, Tuğrul Sarıbeyoğlu E, Şahin Ş, Anak S S. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi. Çocuk Dergisi. 2021;21(1):7-12. https://doi.org/10.26650/jchild.2021.1.844098


ABNT

Yaman, Y.; Elli, M.; Özdilli, K.; Telhan, L.; Bayram, N.; Hazar, V.; Tuğrul Sarıbeyoğlu, E.; Şahin, Ş.; Anak, S.S. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi. Çocuk Dergisi, [Publisher Location], v. 21, n. 1, p. 7-12, 2021.


Chicago: Author-Date Style

Yaman, Yöntem, and Murat Elli and Kürşat Özdilli and Leyla Telhan and Nihan Bayram and Volkan Hazar and Ebru Tuğrul Sarıbeyoğlu and Şifa Şahin and Seniye Sema Anak. 2021. “Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi.” Çocuk Dergisi 21, no. 1: 7-12. https://doi.org/10.26650/jchild.2021.1.844098


Chicago: Humanities Style

Yaman, Yöntem, and Murat Elli and Kürşat Özdilli and Leyla Telhan and Nihan Bayram and Volkan Hazar and Ebru Tuğrul Sarıbeyoğlu and Şifa Şahin and Seniye Sema Anak. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi.” Çocuk Dergisi 21, no. 1 (Sep. 2021): 7-12. https://doi.org/10.26650/jchild.2021.1.844098


Harvard: Australian Style

Yaman, Y & Elli, M & Özdilli, K & Telhan, L & Bayram, N & Hazar, V & Tuğrul Sarıbeyoğlu, E & Şahin, Ş & Anak, SS 2021, 'Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi', Çocuk Dergisi, vol. 21, no. 1, pp. 7-12, viewed 24 Sep. 2021, https://doi.org/10.26650/jchild.2021.1.844098


Harvard: Author-Date Style

Yaman, Y. and Elli, M. and Özdilli, K. and Telhan, L. and Bayram, N. and Hazar, V. and Tuğrul Sarıbeyoğlu, E. and Şahin, Ş. and Anak, S.S. (2021) ‘Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi’, Çocuk Dergisi, 21(1), pp. 7-12. https://doi.org/10.26650/jchild.2021.1.844098 (24 Sep. 2021).


MLA

Yaman, Yöntem, and Murat Elli and Kürşat Özdilli and Leyla Telhan and Nihan Bayram and Volkan Hazar and Ebru Tuğrul Sarıbeyoğlu and Şifa Şahin and Seniye Sema Anak. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi.” Çocuk Dergisi, vol. 21, no. 1, 2021, pp. 7-12. [Database Container], https://doi.org/10.26650/jchild.2021.1.844098


Vancouver

Yaman Y, Elli M, Özdilli K, Telhan L, Bayram N, Hazar V, Tuğrul Sarıbeyoğlu E, Şahin Ş, Anak SS. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi. Çocuk Dergisi [Internet]. 24 Sep. 2021 [cited 24 Sep. 2021];21(1):7-12. Available from: https://doi.org/10.26650/jchild.2021.1.844098 doi: 10.26650/jchild.2021.1.844098


ISNAD

Yaman, Yöntem - Elli, Murat - Özdilli, Kürşat - Telhan, Leyla - Bayram, Nihan - Hazar, Volkan - Tuğrul Sarıbeyoğlu, Ebru - Şahin, Şifa - Anak, SeniyeSema. Hodgkin Lenfoma Nüks ve/veya Kemoterapi Dirençli Olgularda Hematopoetik Kök Hücre Nakli ve Yüksek Doz Kemoterapi: Tek Merkez Deneyimi”. Çocuk Dergisi 21/1 (Sep. 2021): 7-12. https://doi.org/10.26650/jchild.2021.1.844098



ZAMAN ÇİZELGESİ


Gönderim23.12.2020
İlk Revizyon10.03.2021
Son Revizyon16.03.2021
Kabul03.04.2021
Çevrimiçi Yayınlanma17.05.2021

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.